Literature DB >> 12192551

Follow-up of differentiated thyroid cancer.

Furio Pacini1.   

Abstract

The aim of post-surgical follow-up for differentiated thyroid carcinoma is the early identification of the small proportion of patients who have residual disease or develop a recurrence. When total thyroidectomy and radioiodine ablation have been the initial treatment, three powerful tools are available for the follow-up: basal and TSH-stimulated serum thyroglobulin (Tg) measurement, iodine-131 whole body scan (WBS) and neck ultrasound. Serum Tg measurement is the most sensitive and specific marker of differentiated thyroid cancer. Undetectable serum Tg levels are found in the large majority of disease-free patients, while elevated concentrations of serum Tg are associated with the presence of residual or metastatic thyroid tissue. In the last case, WBS under TSH stimulation (either after withdrawal of L-thyroxine therapy or after recombinant human TSH stimulation) and neck ultrasound are the most informative tests for the detection of distant or local metastases, respectively, that require more appropriate treatment (surgery and/or radioiodine therapy). Using this strategy, most patients will achieve definitive cure and will have a normal quality of life.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12192551     DOI: 10.1007/s00259-002-0847-9

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  13 in total

1.  Usefulness of thyroglobulin measurement in needle washouts of fine-needle aspiration biopsy for the diagnosis of cervical lymph node metastases from papillary thyroid cancer before thyroidectomy.

Authors:  Dae-Weung Kim; Se Jeong Jeon; Chang Guhn Kim
Journal:  Endocrine       Date:  2012-02-18       Impact factor: 3.633

2.  Quantification of thyroglobulin, a low-abundance serum protein, by immunoaffinity peptide enrichment and tandem mass spectrometry.

Authors:  Andrew N Hoofnagle; Jessica O Becker; Mark H Wener; Jay W Heinecke
Journal:  Clin Chem       Date:  2008-09-18       Impact factor: 8.327

3.  Short-term outcome of differentiated thyroid cancer patients receiving a second iodine-131 therapy on the basis of a detectable serum thyroglobulin level after initial treatment.

Authors:  Leonardo Pace; Michele Klain; Carmine Albanese; Barbara Salvatore; Giovanni Storto; Andrea Soricelli; Marco Salvatore
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-10-05       Impact factor: 9.236

Review 4.  The role of nuclear medicine in differentiated thyroid cancer.

Authors:  Susanne Kohlfürst
Journal:  Wien Med Wochenschr       Date:  2012-07-20

Review 5.  The path to clinical proteomics research: integration of proteomics, genomics, clinical laboratory and regulatory science.

Authors:  Emily S Boja; Henry Rodriguez
Journal:  Korean J Lab Med       Date:  2011-04

6.  Challenging cases in thyroid cancer: a multidisciplinary approach.

Authors:  Michael Tuttle; Richard Robbins; Steven M Larson; H William Strauss
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-12-10       Impact factor: 9.236

7.  Indications for thyroid cancer surgery in elderly patients.

Authors:  Hiroshi Matsuyama; Iwao Sugitani; Yoshihide Fujimoto; Kazuyoshi Kawabata
Journal:  Surg Today       Date:  2009-07-29       Impact factor: 2.549

8.  Measurement of thyroglobulin by liquid chromatography-tandem mass spectrometry in serum and plasma in the presence of antithyroglobulin autoantibodies.

Authors:  Mark M Kushnir; Alan L Rockwood; William L Roberts; Dev Abraham; Andrew N Hoofnagle; A Wayne Meikle
Journal:  Clin Chem       Date:  2013-02-08       Impact factor: 8.327

9.  False-positive uptake on radioiodine whole-body scintigraphy: physiologic and pathologic variants unrelated to thyroid cancer.

Authors:  Jong-Ryool Oh; Byeong-Cheol Ahn
Journal:  Am J Nucl Med Mol Imaging       Date:  2012-07-10

10.  Clinical use of PET/CT in thyroid cancer diagnosis and management.

Authors:  Fx Sundram
Journal:  Biomed Imaging Interv J       Date:  2006-10-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.